Login
$PRLD
$3.35 -$0.06 (1.76%) After hours

$PRLD SEC Filings

Filed On Filing
16 Nov 2026 10-Q
16 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

10 Sep 2026 8-K: Regulation FD Disclosure

This presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and cli...

11 Aug 2026 10-Q
11 Aug 2026 8-K: Results of Operations and Financial Condition

The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter

08 Jul 2026 SCHEDULE 13G
10 Jun 2026 Form 4: Baker Bros. Advisors Lp, Director and 5 others

Granted 76,000 Non-Qualified Stock Option (right to buy)

10 Jun 2026 Form 4: Dorton Katina, Director

Granted 38,000 Director Stock Option (Right to Buy)

10 Jun 2026 Form 4: Babler Martin, Director

Granted 38,000 Director Stock Option (Right to Buy)

10 Jun 2026 Form 4: Bonita David P, Director

Granted 38,000 Director Stock Option (Right to Buy)

10 Jun 2026 Form 4: Sandor Victor, Director

Granted 38,000 Director Stock Option (Right to Buy)

10 Jun 2026 Form 4: Friedman Paul A, Director

Granted 38,000 Director Stock Option (Right to Buy)

10 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 9, 2026, Prelude Therapeutics Incorporated (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") and the following proposals were approved by the Company's stockholders:

12 May 2026 10-Q
12 May 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

04 May 2026 Form 4: Morris Charles Q, Chief Medical Officer

Granted 450,000 Employee Stock Option (right to buy) ($2.12M)

29 Apr 2026 ARS
29 Apr 2026 DEFA14A
29 Apr 2026 Proxy statement: annual meeting on June 9, 2026

CEO pay $1.3M, down 42% · say-on-pay vote

28 Apr 2026 SCHEDULE 13G

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support